The ongoing shortage of Amoxicillin has been deeply problematic for both healthcare providers and patients. As resupply delays have worsened the national shortage, Americans are reminded of the need for a trusted, reliable domestic source for this critical drug.
At USAntibiotics, the only remaining US manufacturer of Amoxicillin, we are committed to providing a stable supply of antibiotics to healthcare providers and patients across the country. We have expressed deep concern about the offshoring of pharmaceutical production, and continue to encourage the White House and HHS to rectify this issue.
I urge the government to seek assistance in combating this problem domestically. Reliance on foreign manufacturers puts our nation at risk and Americans' lives in danger.
Our 360,000-square-foot facility in Bristol, Tennessee, can produce and store every dose of Amoxicillin needed in the U.S. for the next five years. We stand ready to help solve today's problems and prevent dangerous shortages in the future.
Editor's note: This letter to the editor is in response to the following article Becker's published March 8: Amoxicillin shortage continues as resupply dates are delayed again.